The roles EpCAM plays to enhance the malignancy of gastric cancer
Journal of Cancer Research and Clinical Oncology · 2023
DOI: 10.1007/s00432-023-04767-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Xuewei Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi, China. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guochao Nie.
Abstract (Originalsprache)
BACKGROUND: Gastric cancer (GC) remains a global challenge due to its high morbidity and mortality rates especially in Asia as well as poor response to treatment. As a member of the adhesion protein family and transmembrane glycoprotein, EpCAM expressed excessively in cancer cells including GC cells. The database assay showed that EpCAM is excessively expressed and easily mutated in cancers, especially in early stage of GC. METHODS: To explore the roles EpCAM plays in oncogenesis and progression of GC, the expression of EpCAM was deleted in GC cells with CRISPR/Cas9 method, and then the changes of cell proliferation, apoptosis, motility and motility associated microstructures in EpCAM-deleted GC cells (EpCAM-/-SGC7901) were detected to evaluate the rules EpCAM played. RESULTS: The results showed that EpCAM deletion caused cell proliferation, motility and the development of motility-relevant microstructures inhibited significantly, apoptotic trend and contact inhibition enhanced in EpCAM-deleted GC cells. The results of western blot suggested that EpCAM modulates the expression of epithelial/endothelial mesenchymal transition (EMT) correlated genes. All results as above indicated that EpCAM plays important roles to enhance the oncogenesis, malignancy and progression as a GC enhancer. CONCLUSIONS: Combining our results and published data together, the interaction of EpCAM with other proteins was also discussed and concluded in the discussion. Our results support that EpCAM can be considered as a novel target for the diagnosis and therapy of GC in future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi, China.
- College of P.E and Sports, Beijing Normal University, Beijing, 100875, China.
- School of Medicine, Deakin University, Waurn Ponds, VIC, 3216, Australia.
- Guangxi Key Laboratory of Agricultural Resource Chemistry and Biotechnology, Yulin, 537000, Guangxi, China. bccu518@163.com.
- College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi, China. ychhou@snnu.edu.cn.
Förderung
- Guochao Nie
Zitieren
APA
Zhao, X., Zhao, R., Feng, Y., Qiu, Z., Bai, X., Zhang, D., Zhou, Y., Fang, H., Liu, N., Chen, L., Jia, C., Yuan, Y., Li, X., Duan, W., Nie, G., & Hou, Y. (2023). The roles EpCAM plays to enhance the malignancy of gastric cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04767-2
Vancouver
Zhao X, Zhao R, Feng Y, Qiu Z, Bai X, Zhang D, et al. The roles EpCAM plays to enhance the malignancy of gastric cancer. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-023-04767-2
BibTeX
@article{Zhao2023,
author = {Zhao, Xuewei and Zhao, Ruixia and Feng, Yang and Qiu, Zuchun and Bai, Xue and Zhang, Danying and Zhou, Yujuan and Fang, Hongming and Liu, Niu and Chen, Lirong and Jia, Chenshuang and Yuan, Yue and Li, Xinyao and Duan, Wei and Nie, Guochao and Hou, Yingchun},
title = {The roles EpCAM plays to enhance the malignancy of gastric cancer},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2023},
doi = {10.1007/s00432-023-04767-2}
}
EUVIMED